Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes.
The post With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better appeared first on MedCity News.
]]>Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression.
The post Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression appeared first on MedCity News.
]]>Regardless of the path to market they ultimately take, DTx companies must be poised to harness and deploy data and information that can prove their products’ economic value. Without it, the innovative treatments that they produce will continue to struggle to find success.
The post Digital Therapeutics Find Opportunity in Healthcare Economics Outcomes appeared first on MedCity News.
]]>I look at non-pharmacological approaches like digital therapeutics as having the potential to give someone like me living with chronic pain everything I need to make a healthy recovery: access to digital treatments and clinicians, to community, coaching, and navigation services.
The post Moving Beyond Medicine To Treat Chronic Pain appeared first on MedCity News.
]]>Digital therapeutics have shown how therapy can be delivered effectively through a digital interface, but the bankruptcy of Pear Therapeutics raised questions about whether these technologies can be commercially successful. A panel at the MedCity News INVEST Digital Health conference discussed the promise and pitfalls of these emerging technologies.
The post Digital Medicines Sector Draws Lessons From Pear Therapeutics’ Demise appeared first on MedCity News.
]]>Demand is increasing, yet many payers are still hesitant to cover them – in large part thanks to laws that govern coverage, a lack of clarity regarding coverage approaches, and questions regarding evidence generation for these solutions.
The post DTX Payer Landscape: Barriers and Solutions appeared first on MedCity News.
]]>At the HLTH conference last week, MedCity News’ editorial team interviewed 11 health leaders from a variety of organizations to get a sense of which areas within healthcare will see consolidation over the next 12 months.
The post 4 Areas Within Digital Health That Will See Consolidation Next Year appeared first on MedCity News.
]]>Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today!
The post Digital Therapeutics: A Panacea for Care or Overvalued Health Tech? appeared first on MedCity News.
]]>Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
The post Click Expands to Substance Use Disorder With Indivior Digital Therapeutics Pact appeared first on MedCity News.
]]>Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
The post Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics appeared first on MedCity News.
]]>One of the fastest-growing frontiers of healthcare is Digital Therapeutics (DTx), which utilizes clinically tested software to prevent, treat, and manage a growing range of medical conditions. During Covid-19, governing agencies loosened regulatory requirements and increased incentives for DTx. Fortunately, this propelled innovation, and transitioned DTx from up-and-coming to a high-demand field. The goal was […]
The post What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder appeared first on MedCity News.
]]>The challenge of introducing a novel therapy is nothing new. It has been done again and again, but always from a foundation of compelling evidence…gathered through a rigorous scientific approach that demonstrates quality, safety, efficacy, and a favorable balance of benefits and risks.
The post In Therapeutic Innovation, Digital Must Be Held to the Same Rigor as Biotech appeared first on MedCity News.
]]>Paris-based Sofinnova Partners announced last week that it has launched a new strategy aimed at investing in a new breed of startups that straddle the lines between data and biology.
The post Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences appeared first on MedCity News.
]]>CMS recently established a unique code for AppliedVR’s flagship product, marking the first time a digital therapeutic or immersive therapeutic has ever been placed in an existing benefit category. The eight-week program is a physician-prescribed solution that allows patients to manage their chronic lower back pain without opioids from the comfort of their own home.
The post AppliedVR Earns First Unique CMS Code Ever Granted to a Digital Therapeutic appeared first on MedCity News.
]]>Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.
The post Pear Therapeutics’ Cuts Are Not Enough; ‘Strategic Alternatives’ Among Next Steps appeared first on MedCity News.
]]>As regulatory processes and reimbursements are refined, there needs to be a continued focus on how to maximize the benefits for patients and ensure DTx can play a role in improving outcomes. The key to this is integration into the clinical workflow.
The post The Drive to Adopt Digital Therapeutics: Where do we Stand? appeared first on MedCity News.
]]>Earlier this year, CMS implemented a new Level II Healthcare Common Procedure Coding System (HCPCS) code for “prescription digital behavioral therapy,” which makes it easier for commercial and Medicaid plans to cover these therapies. Additionally
The post The Challenges, Potential, and Future of Digital Therapeutics in Healthcare appeared first on MedCity News.
]]>Ultimately, it is anticipated that CMS will further expand the use of reimbursable RTM beyond respiratory and MSK care and incorporate patient-reported information as a requirement for reimbursement of certain remote services.
The post RTM Reimbursement Represents a New Age for Digital Therapeutics appeared first on MedCity News.
]]>Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company’s medication by their physician.
The post How pharma companies can leverage asynchronous telemedicine appeared first on MedCity News.
]]>By placing the power to detect atrial fibrillation into the hands of 6 billion global smartphone users, validation of further physiological parameters will be expedited and the subsequent adoption of this technology into DTx will enable the low-cost tools required to remove barriers to care and improve heart health across the globe.
The post Why better heart health worldwide is now within reach appeared first on MedCity News.
]]>A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.
The post Overcoming obstacles in digital medicine appeared first on MedCity News.
]]>Operational efficiency and visibility brought on by digital transformation can help improve how pharmaceutical manufacturers do their critical part in improving equitable access and availability of medicine around the world.
The post A call to action for pharma manufacturers: Rise to the challenge of global medicine access with the help of digitalization appeared first on MedCity News.
]]>A webinar sponsored by Twilio will share predictions for driving personalized care and engagement in healthcare and life sciences in 2022.
The post The outlook for tech-enabled personalized care in healthcare and life sciences appeared first on MedCity News.
]]>The Series D round of funding makes Biofourmis a unicorn valued at $1.3 billion. CEO and founder Kuldeep Singh Rajput said that the new capital will be used to expand his company’s remote-monitoring technologies and continue development of digital therapeutics, both as companions to traditional drugs and as monotherapies.
The post Biofourmis adds $300M to ramp up in virtual care, digital therapy clinical trials appeared first on MedCity News.
]]>In the U.S., EndeavorRx has been cleared to help in improving attention function as measured by computer-based testing in children ages 8-12 years who have primarily inattentive or combined-type ADHD who struggle with maintaining attention.
The post New study shows first FDA-cleared video game treatment for pediatric ADHD improves brain function appeared first on MedCity News.
]]>The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid use and substance use disorders.
The post Pear’s digital therapeutic for alcohol use disorder gets breakthrough designation appeared first on MedCity News.
]]>Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
The post Click Therapeutics raises $52M, looks to advance digital therapeutics appeared first on MedCity News.
]]>VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work.
The post Investors see promise in digital health — the challenge is adoption appeared first on MedCity News.
]]>Luminopia, a startup with a digital therapeutic for amblyopia, or lazy eye, recently published the results of a phase 3 study showing its TV-based treatment can improve vision in kids’ non-dominant eye. Patients don a headset where images are altered to make them use both eyes.
The post Startup testing video-based treatment for ‘lazy eye’ touts Phase 3 results appeared first on MedCity News.
]]>Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment.
The post Neuroglee looks to Mayo partnership, digital therapeutics to tackle mild cognitive impairment appeared first on MedCity News.
]]>